Based in Japan and India. Has led to 1 successful fundraise in Japan. Been working the space of Venture Capital and Private Equity for the last 3 years.

Aristea Therapeutics (Aristea), a clinical-stage drug development company developing novel therapies for the treatment of serious inflammatory diseases, today announced that it has secured $15M from Novo Holdings A/S (Novo Holdings) in the completed Series A funding package. Aristea also acquired exclusive global rights under its lead program RIST4721 from AstraZeneca. Aristea plans to launch a phase 2 clinical study in early 2019. With regard to financing, Tiba Aynechi, Ph D, Ken Harrison, Ph, D of Novo Ventures (US), Inc. was appointed to the Board of Directors of Aristea

The Aristea team has extensive experience in the development and commercialization of novel medicines, highlighted by eight previous drug product approvals in a wide range of therapeutic categories, including neuroscience, diabetes/metabolic diseases, inflammation, oncology and infectious diseases. Founder, President and CEO of Aristea, James Mackay, formerly President and CEO of Ardea Biosciences (acquired by AstraZeneca in 2012) Prior to Ardea, Mackay held senior executive positions at AstraZeneca, where he led the development and commercialization of drugs across a wide range of treatment areas. The Aristea team will leverage their collective industry expertise and proven success in developing and marketing drugs to form synergistic partnerships and build a pipeline of novel drugs.

“At Aristea, we are passionate drug developers committed to bringing new medicines to patients through a focused, diligent and agile approach. We believe that this approach, coupled with the financial support of Novo Holdings and our proven track record in drug development, will give Aristea a significant advantage in building a valuable pipeline,” said James Mackay, President and CEO of Aristea Therapeutics. “We look forward to building up the organization and moving forward with RIST4721 through Phase 2. “That’s right.

“We are very pleased to support an experienced team with a deep insight into the lead program. We look forward to supporting them as they develop a drug that can significantly improve the lives of patients with conditions that are not approved for treatment today,” said Tiba Aynechi, Partner, Novo Ventures.

About New Holdings

Novo Holdings is a private limited liability company wholly owned by the Novo Nordisk Foundation in Denmark. The company is the holding company of the Novo Group, consisting of Novo Nordisk A/S, Novozymes A/S and NNIT A/S, and is responsible for managing the assets of the Foundation. In addition to being the main shareholder of the Novo Group companies, Novo Holdings supplies seed and venture capital to development companies, holds significant ownership positions in well-established life science companies and manages a broad portfolio of financial assets. Novo Ventures, Inc. It is wholly owned by Novo Holdings and provides consulting services to Novo Holdings Read more on www Novo-holdings Well, dk

Aristea Therapeutics

Aristea Therapeutics (Air-iss-tay-uh) is a clinical drug development company developing novel therapies for the treatment of serious inflammatory diseases. The Aristea team draws on its broad industry expertise and proven success in developing drugs to form synergistic partnerships and build a pipeline of novel drugs. The lead program of Aristea, RIST4721, is currently in phase 2 clinical development. Aristea is based in San Diego, CA. Please visit www to learn more. Aristeatx: Come on,

Please note that this piece of work originally appeared in English at https://www.vcnewsdaily.com/Aristea%20Therapeutics/venture-funding.php. As Investocracy aims to bring global startup news and updates in both English and Japanese to you, it’s important that we attribute original source to you. If you have any questions/concerns please write to us at contact@investocracy.co

Leave a Reply

Your email address will not be published. Required fields are marked *